Count on the Advancement of DNA Medicine with Inovio Stock



a close up of a piece of paper: the inovio (INO) logo covered up by pills and a syringe


© Source: Ascannio / Shutterstock.com
the inovio (INO) logo covered up by pills and a syringe

Too often, traders tend to pigeonhole certain stocks. For example, some folks might think of Inovio Pharmaceuticals (NASDAQ:INO) as a Covid-19 vaccine company and INO stock as nothing more than a novel coronavirus stock.



a close up of a piece of paper: the inovio (INO) logo covered up by pills and a syringe


© Provided by InvestorPlace
the inovio (INO) logo covered up by pills and a syringe

Don’t get me wrong. Inovio absolutely is part of the nationwide and global battle against the coronavirus. But there’s no need to pigeonhole INO as just a coronavirus stock.

The company works diligently to develop DNA medicines to treat a range of infectious diseases and cancers. There’s positive news about Inovio’s development of its Covid-19 vaccine candidate, INO-4800, but there’s also good news in other departments.

Therefore, it’s worth investigating both Inovio’s Covid-19 vaccine efforts as well as the company’s progress in other areas. That way, you can get a complete picture of this fascinating biotech company with breakout potential.

INO Stock at a Glance

If the market is telling us anything about INO stock, it’s that the shares are underappreciated and undervalued. You might even say that INO is one of the biotech sector’s most compelling bargains at the moment.

INO stock achieved its 52-week high of $31.71 on June 29, but somehow the market decided that this wasn’t the right price for the stock. As a result, a gradual sell-off commenced.

Loading...

Load Error

At the close of Nov. 24, INO stock settled slightly above $10 per share. Sometimes people say that they like to buy low and sell high. When the time comes to buy a stake in a promising company at a low price, however, those same traders tend to chicken out.

If you hesitate, you might miss out on a rare opportunity with INO stock. Even if you’re only thinking relatively short-term (i.e., as a swing trader), there’s potential here. INO has a tendency to spike quickly from time to time, just like it did in mid-September. This could easily happen again if there’s good news.

Not Just Covid-19

I’m going to take a different approach from many commentators and veer away from the topic of Covid-19 vaccine candidates. Let’s not discount the significance of the other conditions that Inovio is working to address.

One example is INO-3107, Inovio’s DNA medicine candidate designed to treat Recurrent Respiratory Papillomatosis (RRP). Inovio just dosed its first subject with INO-3107 in a Phase 1/2 clinical trial for this condition.

RRP is a very unfortunate and rare ailment. Caused by certain types of human papillomavirus (HPV), RRP is incurable and causes non-cancerous tumor growths that lead to life-threatening airway obstructions.

Usually, surgery is used to treat RRP. Furthermore, sometimes patients need multiple surgeries, which can severely impact their quality of life. The U.S. Food and Drug Administration (FDA) already granted INO-3107 Orphan Drug Designation, so it’s great to hear that there’s progress in developing this less invasive treatment.

Advancing Other DNA Medicines

For

Read more

Should You Stock Up For A Second Coronavirus Wave? Stores Are

With infectious disease experts in the U.S. calling for residents to buckle in for winter, shoppers might start to plan on another grocery stock up, but do they really need to?

Edward McLaughlin, a professor of food industry management at Cornell University, was quoted in Yahoo! News saying stores may be better prepared for a second round of pandemic panic-buying. Like shoppers, “grocery stores and food retailers are stockpiling products,” he said.

“Retailers have learned key lessons from the pandemic,” he added. “Shoppers will be loyal even if you don’t have the fancy extras, as long as you have the basics.”

Still, some shoppers may want to be prepared. Cases of the novel coronavirus are spreading in the U.S. and throughout Europe. Colder temperatures in the Northern Hemisphere inhibit the body’s natural suppression tactics, meaning people will likely be more vulnerable to infections as the weather cools.

Earlier this month, Dr. Peter Hotez, the Dean of the National School of Tropical Medicine at Baylor College of Medicine, told CNN an uptick in COVID-19 cases was inevitable.

“This winter — this November, December, January, February — could be the worst time in our epidemic,” he said. “Get ready to hunker down.”

At the beginning of the COVID-19 pandemic in March, that hunkering down meant fewer trips to the grocery store and carts full of goods from bread flour to toilet paper– arguably the hottest commodity of 2020. A stubborn pandemic could prompt shoppes to start hoarding goods again. Higher sales for toilet paper and other consumer staples in Europe and the United States boosted Procter & Gamble’s quarterly results. Photo: GETTY IMAGES NORTH AMERICA / CHIP SOMODEVILLA

Source Article

Read more

Business News | Stock and Share Market News


By

Read more